Richard, you beat me to Post #500. Anyway, I don't really find the
press release confusing, but it certainly is not really important.
When was this conference? I was just in Tahoe last week for my
company's off-site meeting. If I knew that Dr. Babish was there, I
would have tried to meet with him.
Among the seven patients in the original compassionate-use trial,
one had prostate cancer. In addition, PN27,1 was also reported to
have efficacy agianst an in vitro assay, which Paracelsian developed.
And PRLN has begun a much larger compassionate-use trial to be
completed in the fall. Ho, hum. There is nothing new here. It is
old, in fact.
The only thing important here is that Paracelsian was invited to be
there. I guess this is an honor; I'm not familiar with the CaP CURE
retreats. Such an "honor" will probably not excite any investors.
I did learn something new, however: PN27,1 is also called AndroCar.
So we have AndroVir and AndroCar. Where do these names come from?
Does anyone know?
Rick |
